

Age Related Macular Degeneration - Pipeline Review, H1 2020

<https://marketpublishers.com/r/AF9DE27C667EN.html>

Date: June 2020

Pages: 864

Price: US\$ 2,500.00 (Single User License)

ID: AF9DE27C667EN

Abstracts

Age Related Macular Degeneration - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Age Related Macular Degeneration - Pipeline Review, H1 2020, provides an overview of the Age Related Macular Degeneration (Ophthalmology) pipeline landscape. Age related macular degeneration is the most common reason for vision loss in people aged above 50. It results in depreciation of the macula that may lead to distorted or blurry central vision. The predisposing factors involved are age, smoking, sunlight, heredity etc. Symptoms include development of blind spot and hazy vision. The condition may be treated by photodynamic therapy, radiation therapy and medication such as anti-angiogenic drugs.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Age Related Macular Degeneration - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Age Related Macular Degeneration (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Age Related Macular Degeneration (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Age Related Macular Degeneration and features dormant and discontinued projects. The guide covers therapeutics under

Development by Companies/Universities/Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 1, 21, 30, 33, 3, 169, 40 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 17 and 1 molecules, respectively. Age Related Macular Degeneration (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Age Related Macular Degeneration (Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Age Related Macular Degeneration (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Age Related Macular Degeneration (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Age Related Macular Degeneration (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and

understand from the know-how what drove them from pipeline.

Contents

Introduction

Age Related Macular Degeneration - Overview

Age Related Macular Degeneration - Therapeutics Development

Age Related Macular Degeneration - Therapeutics Assessment

Age Related Macular Degeneration - Companies Involved in Therapeutics Development

Age Related Macular Degeneration - Drug Profiles

Age Related Macular Degeneration - Dormant Projects

Age Related Macular Degeneration - Discontinued Products

Age Related Macular Degeneration - Product Development Milestones

Appendix

List Of Tables

LIST OF TABLES

Number of Products under Development for Age Related Macular Degeneration, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Products under Development by Companies, H1 2020

Products under Development by Universities/Institutes, H1 2020

Number of Products by Stage and Target, H1 2020

Number of Products by Stage and Mechanism of Action, H1 2020

Number of Products by Stage and Route of Administration, H1 2020

Number of Products by Stage and Molecule Type, H1 2020

Age Related Macular Degeneration - Pipeline by 3SBio Inc, H1 2020

Age Related Macular Degeneration - Pipeline by 4D Molecular Therapeutics Inc, H1 2020

Age Related Macular Degeneration - Pipeline by Abpro Corp, H1 2020

Age Related Macular Degeneration - Pipeline by Abzyme Therapeutics LLC, H1 2020

Age Related Macular Degeneration - Pipeline by Active Biotech AB, H1 2020

Age Related Macular Degeneration - Pipeline by AdAlta Ltd, H1 2020

Age Related Macular Degeneration - Pipeline by Adverum Biotechnologies Inc, H1 2020

Age Related Macular Degeneration - Pipeline by Aerie Pharmaceuticals Inc, H1 2020

Age Related Macular Degeneration - Pipeline by Aerpio Pharmaceuticals Inc, H1 2020

Age Related Macular Degeneration - Pipeline by Aevitas Therapeutics Inc, H1 2020

Age Related Macular Degeneration - Pipeline by Affilogic SAS, H1 2020

Age Related Macular Degeneration - Pipeline by Aibios Co Ltd, H1 2020

Age Related Macular Degeneration - Pipeline by Aiviva BioPharma Inc, H1 2020

Age Related Macular Degeneration - Pipeline by Zhejiang Doer Biologics Corp, H1 2020

Age Related Macular Degeneration - Dormant Projects, H1 2020

Age Related Macular Degeneration - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Age Related Macular Degeneration, H1 2020

Number of Products under Development by Companies, H1 2020

Number of Products under Development by Universities/Institutes, H1 2020

Number of Products by Top 10 Targets, H1 2020

Number of Products by Stage and Top 10 Targets, H1 2020

Number of Products by Top 10 Mechanism of Actions, H1 2020

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020

Number of Products by Top 10 Routes of Administration, H1 2020

Number of Products by Stage and Top 10 Routes of Administration, H1 2020

Number of Products by Top 10 Molecule Types, H1 2020

Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

3SBio Inc

4D Molecular Therapeutics Inc

Abpro Corp

Abzyme Therapeutics LLC

Active Biotech AB

AdAlta Ltd

Adverum Biotechnologies Inc

Aerie Pharmaceuticals Inc

Aerpio Pharmaceuticals Inc

Aevitas Therapeutics Inc

Affilogic SAS

Aibios Co Ltd

Aiviva BioPharma Inc

Aldeyra Therapeutics Inc

Alexion Pharmaceuticals Inc

Alkahest Inc

Alkeus Pharmaceuticals Inc

Allegro Ophthalmics LLC

Allergan Ltd

Allgenesis Biotherapeutics Inc

Alpine Biotherapeutics Corp
Alteogen Inc
Alzheon Inc
Amarna Therapeutics BV
Amgen Inc
Amicogen Inc
Amyndas Pharmaceuticals LLC
AngioGenex Inc
Anida Pharma Inc
Annexon Inc
Apellis Pharmaceuticals Inc
Apexian Pharmaceuticals Inc
Apexigen Inc
Applied Genetic Technologies Corp
AptaBio Therapeutics Inc
Aptamer Sciences Inc
Ascentage Pharma Group International
Asclepiumm Taiwan Co Ltd
AsclepiX Therapeutics Inc
Astellas Pharma Inc
Avixgen Inc
Beijing Eastern Biotech Co Ltd
BellBrook Labs LLC
Beta Therapeutics Pty Ltd
Bio-Thera Solutions Ltd
BIOCND Inc
Biocure Technology Inc
Bioeq GmbH
Biogen Inc
Biokine Therapeutics Ltd
Biomics Biotechnologies Co Ltd
Biophytis SA
Boehringer Ingelheim International GmbH
Bridge Biotherapeutics Inc
Cadila Healthcare Ltd
Catalyst Biosciences Inc
CDR-Life Inc
Cell Care Therapeutics Inc
Cell Cure Neurosciences Ltd

Celon Pharma SA
Charlesson LLC
Chengdu Kanghong Pharmaceuticals Group Co Ltd
Chong Kun Dang Pharmaceutical Corp
CHS Pharma Inc
Cinnagen Co
Clayton Biotechnologies Inc
Clearside BioMedical Inc
Clover Biopharmaceuticals
Coherus BioSciences Inc
CureLab Oncology Inc
Daiichi Sankyo Co Ltd
DNX Biopharmaceuticals Inc
Dobecure SL
Dong-A Socio Holdings Co Ltd
Drive Therapeutics LLC
EirGenix Inc
Elasmogen Ltd
Emerald Organic Products Inc
Envisia Therapeutics Inc
Enzene Biosciences Ltd
Epygen Biotech Pvt Ltd
Everglades Biopharma LLC
Exonate Ltd
Eye Co Pty Ltd
Eyedesis Biosciences LLC
EyeGate Pharmaceuticals Inc
EyePoint Pharmaceuticals Inc
Eyestem Research Pvt Ltd
Eyevensys SAS
F. Hoffmann-La Roche Ltd
Feramda Ltd
FirstString Research Inc
Formycon AG
Galimedix Therapeutics Ltd
Gemini Therapeutics Inc
Gene Signal International SA
Gene Techno Science Co Ltd
Genentech Inc

Generation Bio Co
Generium
Generoath Co Ltd
GenSight Biologics SA
Graybug Vision Inc
Gyroscope Therapeutics Ltd
Hanlim Pharm Co Ltd
HEALIOS KK
Hemera Biosciences Inc
Hengenix Biotech Inc
HK inno.N Corp
Huabo Biopharm Co Ltd
Huons Global Co Ltd
Ichor Therapeutics Inc
Iconic Therapeutics Inc
Ildong Pharmaceutical Co Ltd
Immupharma Plc
Inflammasome Therapeutics Inc
Innovent Biologics Inc
Ionis Pharmaceuticals Inc
Isarna Therapeutics GmbH
iTherapeutics Corp
iVeena Delivery Systems Inc
IVERIC bio Inc
Jeil Pharmaceutical Co Ltd
Johnson & Johnson
JW Pharmaceutical Corp
Kala Pharmaceuticals Inc
Kalos Therapeutics Inc
Katairo GmbH
Kodiak Sciences Inc
Kubota Vision Inc
Kuur Therapeutics Ltd
Kyowa Kirin Co Ltd
Lead Discovery Center GmbH
Lin Bioscience Inc
Lineage Cell Therapeutics Inc
Lupin Ltd
Luye Pharma Group Ltd

Mabion SA
MacuCLEAR Inc
maintect GmbH
Mediolanum farmaceutici SpA
MeiraGTx Holdings Plc
MetiMedi Pharmaceuticals Co Ltd
MitolImmune Therapeutics Inc
Mitotech SA
Mitsubishi Tanabe Pharma Corp
Mor Research Applications Ltd
Mperia Therapeutics Inc
NanoScope Technologies LLC
Nanoscope Therapeutics Inc
Neovacs SA
NeuExcell Therapeutics Inc
Nextgen Bioscience
NGM Biopharmaceuticals Inc
Novartis AG
NovelMed Therapeutics Inc
Novelty Nobility Inc
Noveome Biotherapeutics Inc
OccuRx Pty Ltd
Ocugen Inc
Ocular Therapeutix Inc
OcuNexus Therapeutics Inc
ODIN Biotech Partners LLC
OliX Pharmaceuticals Inc
Omeros Corp
ONL Therapeutics Inc
Opthea Ltd
Outlook Therapeutics Inc
Oxford BioMedica Plc
Oxstem Ltd
Oxurion NV
PanOptica Inc
Paras Biopharmaceuticals Finland Oy
Pfizer Inc
Phanes Therapeutics Inc
PharmAbcine Inc

Phio Pharmaceuticals Corp
Phision Therapeutics
PlantForm Corp
Pleryon Therapeutics Ltd
Polus Inc
Profarma
Qilu Pharmaceutical Co Ltd
Reflexion Pharmaceuticals Inc
Regen BioPharma Inc
Regeneron Pharmaceuticals Inc
RegenxBio Inc
Reliance Life Sciences Pvt Ltd
RemeGen Ltd
Retrotope Inc
RheinCell Therapeutics GmbH
Ribomic Inc
RiniSight Inc
Ripple therapeutics Corp
Samjin Pharm Co Ltd
Samsung Bioepis Co Ltd
SanBio Company Limited
SciFluor Life Sciences LLC
Semathera Inc
Senju Pharmaceutical Co Ltd
Shanghai Junshi Bioscience Co Ltd
Shanghai United Cell Biotechnology Co Ltd
Sigilon Therapeutics Inc
SiNOPSEE Therapeutics Pte Ltd
Splash Pharmaceuticals Inc
Stealth BioTherapeutics Corp
Stuart Therapeutics Inc
Sumitomo Dainippon Pharma Co Ltd
Surrozen Inc
Sustained Nano Systems LLC
Suzhou Kintor Pharmaceutical Inc
Suzhou Stainwei Biotech Inc
Sylentis SAU
TaeJoon Pharmaceuticals Co Ltd
Tarsius Pharma Ltd

TechnoPhage SA
Topadur Pharma AG
TOT Biopharm Co Ltd
Translatum Medicus Inc
TreeFrog Therapeutics SAS
Visgenx Inc
Wellstat Ophthalmics Corp
Xbrane Biopharma AB
Xcovery Holding Co LLC
YD Life Science Co
Zhejiang Doer Biologics Corp

I would like to order

Product name: Age Related Macular Degeneration - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/AF9DE27C667EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/AF9DE27C667EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970